Error: The job that you were looking for either does not exist or is no longer open.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Medical Science Liaison provides a vital role to the organization by bridging internal strategy with external medical insights. Through interactions with the healthcare community, the Medical Science Liaison supports disease awareness activities, participates in scientific exchange, and obtains valuable information regarding unmet medical needs and current treatment paradigms to help guide executive decisions. As part of an emerging US and global organization, the Medical ScienceLiaison will also make significant contributions to processes, procedures, and best practices within the developing organization, serve as a medical resource to healthcare providers, clinical investigators and clinical study sites, and healthcare decision makers regarding the organization’s investigational and marketed products, and support product commercialization. The Medical Science Liaison will report directly to the Field Medical Director, Medical Affairs.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Medical Science Liaison provides a vital role to the organization by bridging internal strategy with external medical insights. Through interactions with the healthcare community, the Medical Science Liaison supports disease awareness activities, participates in scientific exchange, and obtains valuable information regarding unmet medical needs and current treatment paradigms to help guide executive decisions. As part of an emerging US and global organization, the Medical ScienceLiaison will also make significant contributions to processes, procedures, and best practices within the developing organization, serve as a medical resource to healthcare providers, clinical investigators and clinical study sites, and healthcare decision makers regarding the organization’s investigational and marketed products, and support product commercialization. The Medical Science Liaison will report directly to the Field Medical Director, Medical Affairs.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Director, National Sales will establish and execute a plan to meet and exceed sales expectations of edaravone (MCI-186), an innovative solution approved in Japan and granted Orphan Drug status by the FDA for patients suffering from Amyotrophic Lateral Sclerosis (ALS), and for future launch brands and product acquisitions. As part of a commercial organization, the incumbent will play a critical role in shaping the sales function and strategy.
The Director, National Sales will hire, develop, and lead the field sales organization and will work effectively within the broader team to ensure seamless alignment and execution of the broader organization goals and launch plan objectives.
The position will require 50% – 60% travel and must be based within 1 hour of a major airport.
Entrepreneurial Spirit, Rooted in Tradition.
Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) based in Toronto, is a wholly owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), which touts a storied reputation more than 300 years in the making. Our parent company, Mitsubishi Tanabe Pharma Corporation (MTPC) - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).
MTP-C’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in Canadian markets. The company handles sales, marketing, market access, and business development functions. MTP-C is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness and currently seeking motivated professionals who share our vision of scientific excellence, innovation, and unwavering dedication to improving the lives of patients.
The Medical Science Liaison (MSL) provides a vital role to the organization by bridging internal strategy with external medical insights. Through interactions with the healthcare community, the MSL supports disease awareness activities, participates in scientific exchange, and obtains valuable information regarding unmet medical needs and current treatment paradigms to help guide executive decisions. As part of an emerging Canadian and global organization, the MSL will also make significant contributions to processes, procedures, and best practices within the developing organization, serve as a medical resource to healthcare providers, clinical investigators and clinical study sites, and healthcare decision makers regarding the organization’s investigational and marketed products, and support product commercialization. The MSL will report directly to the Medical Director, Medical Affairs.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.
Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).
MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets. In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022. The company handles research, clinical development, sales, marketing, medical affairs, and business development functions. MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.
The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.
The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.